

Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, October 3rd, 2024
1:05 PM - 4:45 PM
Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Patrick DeMartino, MD; Bridget Bradley, PharmD; MD; Douglas Carr, MD; Russ Huffman, PMHNP; Tim Langford, PharmD; Eddie Saito, PharmD; Jeanne Savage, MD; Samara Stevens, ND

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Megan Herink, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells; Dee Weston, JD; Jennifer Bowen; Michael Yu

Audience: Shirley Quach*, Novartis; Lisa Carman*, Genentech; Lynda Finch*, Biogen; Brian Denger *, Parent Project Muscular Dystrophy; Armen Khachatourian*, Sarepta; Erika Finanger*, OHSU; Mark Kantor, AllCare Health; James Day, Texas Pharmaceutical Initiative; Britt Manning, Indivior; Bill McDougall, Biogen; Reina Rittman, Intra-Cellular Therapeutics; Robb Nutt, OR Dept of Corrections; Lindsey Walter, Novartis; Jenny Todenhagen, Genentech; Donesha Belin, UHA; Raya Nematian; Tammi Ocumpaugh, Otsuka; Leanne Yantis; Bethany Freel, Industry MSL; Tony Salicos; Nirmal Ghuman, J&J; Divine Marcelo, Amgen; Tina Shriner, Abbvie; Courtney Ho; Elva Van Devender, Umpqua Health; Denzell Sabado, Genentech; Clarissa Etter; Lori McDermott, Viking HCS; Mike Donabedian, Sarepta; Jim Cromwell, Sarepta; Adam Gold; Gary Parenteau, Dexcom; Tracy Copeland, Sarepta; Lisa Pulver, J&J; Chris Ferrin, IHN; Emily Cooper, NS Pharma; Bryan Armstrong, CareOregon; Melissa Snider, Gilead

(*) Provided verbal testimony

I. CALL TO ORDER


- A. Roll Call & Introductions
 - Called to order at approx. 1:05 p.m., introductions by Committee and staff
- B. Conflict of Interest Declaration – no new conflicts of interest were declared
- C. Approval of Agenda and August 2024 Minutes presented by Roger Citron, RPh
ACTION: Motion to approve, 2nd, all in favor with one abstention
- D. Department Update provided by Andrew Gibler, PharmD

II. CONSENT AGENDA TOPICS

- A. P&T Annual Report
- B. CMS Annual Report
- C. Hepatitis C Direct-Acting Antivirals Literature Scan
Recommendations:
 - No changes to the PDL are recommended based on review of the evidence
 - Retire Pegylated Interferons and Ribavirins prior authorization (PA) criteria
 - Evaluate costs in executive session
- D. Preferred Drug List (PDL) Old Business: Diabetes, Insulins
Recommendation:
 - No changes to the PDL are recommended based on review of the evidence
 - Evaluate costs in executive session
- E. Oncology Prior Authorization (PA) Updates
Recommendation:
 - Add: Tecelra[®] (afamitresgene autoleucel); Lymphir[™] (denileukin diftitox-cxdl); Rytelo[™] (imetelstat); Lazcluze[™] (lazertinib); Hercessi[™] (trastuzumab-strf); and Voranigo[®] (vorasidenib) to Table 1 in the Oncology Agents PA criteria
- F. Orphan Drug Policy Updates
Recommendation:
 - Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of Iqirvo[®] (elafibranor); Yorvipath[®] (palopegteriparatide); and Livdelzi[®] (seladelpar) based on FDA-approved label**ACTION: Motion to approve, 2nd, all in favor**

III. DUR NEW BUSINESS

- A. Immunoglobulins Literature Scan and Drug Use Evaluation (DUE):
Kathy Sentena, PharmD; Sarah Servid, PharmD
Recommendation:
 - No changes to the PDL are recommended based on review of the evidence



- Implement proposed PA criteria for non-preferred pharmacy claims to support off-label use of Ig for evidence supported diagnoses
 - Evaluate medication costs in executive session
- ACTION: Motion to approve, 2nd, all in favor**

IV. PREFERRED DRUG LIST (PDL) NEW BUSINESS

A. Multiple Sclerosis Drug Effectiveness Review Project (DERP) Summary:

Deanna Moretz, PharmD

Recommendations:

- Maintain ublituximab as non-preferred on the PDL
- Add ublituximab to the PA criteria for injectable MS drugs
- Update the PA criteria as proposed
- Evaluate medication costs in executive session

Public Comment: Shirley Quach, Novartis; Lisa Carman, Genentech; Lynda Finch, Biogen

ACTION: The Committee recommended removing question #4 - requiring step therapy - from the Tysabri PA criteria and to add a JC virus titer evaluation for Ocrevus (ocrelizumab) in Table 2 of the PA criteria for injectable MS drugs

Motion to approve, 2nd, all in favor

B. Testosterone for Hypogonadism Class Update: David Engen, PharmD

Recommendations:

- No changes to the PDL are recommended based on review of the evidence
- Update Testosterone PA criteria as proposed to clarify medically appropriate use
- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

C. Inflammatory Bowel Disease (IBD) Class Update: Deanna Moretz, PharmD

Recommendations:

- No changes to the PDL are recommended for the oral and rectal agents for IBD, based on review of the evidence
- Make Tarpeyo[®] (budesonide 4 mg DR caps) and Eohilia[™] (budesonide oral susp) non-preferred and add to oral glucocorticoids class
- Implement PA criteria for Budesonide Oral Suspension
- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

D. Duchenne Muscular Dystrophy Class Update: Sarah Servid, PharmD

Recommendations:



- Update PA criteria to incorporate the expanded indication for delandistrogene moxeparvovec and givinostat
- No changes to the PDL are recommended based on review of the evidence
- Evaluate costs in executive session

Public Comment: Brian Denger, Parent Project Muscular Dystrophy; Armen Khachatourian, Sarepta; Erika Finanger, OHSU

ACTION: Motion to approve, 2nd, all in favor

E. Antacids Class Updates and NDE: Kathy Sentena, PharmD; Sarah Servid, PharmD

Recommendations:

- No changes to the PDL are recommended based on review of the evidence
- Maintain vonoprazan dual and triple therapy combinations as non-preferred on the PDL for the treatment of *H.pylori*
- Require PA for Vonoprazan monotherapy as proposed and remove reference to Prioritized List in the PPI PA criteria
- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

V. EXECUTIVE SESSION

Members Present: Stacy Ramirez, PharmD; Patrick DeMartino, MD; Bridget Bradley, PharmD; Russ Huffman, PMHNP; Tim Langford, PharmD; Eddie Saito, PharmD; Jeanne Savage, MD; Samara Stevens, ND

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Megan Herink, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells

VI. RECONVENE for PUBLIC RECOMMENDATIONS

A. Hepatitis C Direct-Acting Antivirals Literature Scan


Recommendation: No PDL changes recommended

ACTION: Motion to approve, 2nd, all in favor

B. PDL Old Business: Diabetes, Insulins

Recommendations: Make Levemir® preparations (insulin detemir), Novolog® and generics preparations (insulin aspart), Apidra® preparations (insulin glulisine), and Novolog® mixes and generic preparations (insulin aspart mix) non-preferred

ACTION: Motion to approve, 2nd, all in favor



C. Immunoglobulins Literature Scan

Recommendations: Make Hizentra[®], Privigen[®], and Gammagard Liquid[®] preferred; Make Gamunex-C[®] non-preferred; and make all others without PDL status nonpreferred

ACTION: Motion to approve, 2nd, all in favor

D. Multiple Sclerosis DERP Summary

Recommendation: No PDL changes recommended

ACTION: Motion to approve, 2nd, all in favor

E. Testosterone for Hypogonadism Class Update

Recommendation: No PDL changes recommended

ACTION: Motion to approve, 2nd, all in favor

F. Inflammatory Bowel Disease Class Update

Recommendation: Make mesalamine DR tablets (both strengths) preferred

ACTION: Motion to approve, 2nd, all in favor

G. Duchenne Muscular Dystrophy Class Update

Recommendation: Make Emflaza[®] (deflazacort) tablets (brand only) preferred with clinical PA

ACTION: Motion to approve, 2nd, all in favor

H. Antacids Class Updates and NDE

Recommendation: Make esomeprazole magnesium capsule DR and Talicia[®] preferred; and make dexlansoprazole capsule DR BP non-preferred

ACTION: Motion to approve, 2nd, all in favor

VII. ADJOURN